



22-23 January 2024

Poster List

Alphabetical by first presenting author surname

Note to presenters: all content including board numbers is subject to change. Please do not include your board number on your poster.

Board Number	Theme	Poster
1	Other	<p>Dynamic Biobanking for Advancing Breast Cancer Research</p> <p><u>Maryam Abdollahyan</u>¹, Emanuela Gadaleta¹, The Breast Cancer Now Tissue Bank^{1,2,3}, Penelope Ottewell², Angela Cox², Valerie Speirs³, Louise Jones¹, Claude Chelala¹</p> <p>¹Barts Cancer Institute, Queen Mary University of London, UK, ²School of Medicine and Population Health, University of Sheffield, UK, ³The Institute of Medical Sciences, University of Aberdeen, UK</p>
2	Other	<p>Association between built environment factors and post-menopausal breast cancer risk: Alberta's Tomorrow Project</p> <p><u>Mohadeseh Ahmadi</u>¹, Trevor Dummer²</p> <p>¹University Of British Columbia, Vancouver, ²University Of British Columbia, Vancouver</p>
3	Pathology	<p>Correlation Between Radiological Findings and Histopathological Diagnosis of Breast Diseases: Retrospective Review Over Sixth Years in King Fahad University Hospital in Eastern Province, Saudi Arabia</p> <p><u>Sadeem Aljamaan</u>¹, Rahaf Alghamdi¹, Reem Hariri¹, Batool Alotaibi¹, Batool Alsenan¹, Lama Althunayyan¹, Areej Alnemer¹</p> <p>¹Imam Abdulrahman Bin Faisal University, Dammam</p>
4	Metastatic breast cancer	<p>Stress Hormone Modulation of Migration and Invasion in Breast Cancer Cell Lines: A Comparative Analysis</p> <p><u>Andra Antohi</u>¹, Melanie Flint¹, Hazel Hunt²</p> <p>¹University Of Brighton, ²Corcept Therapeutics</p>
5	Other	<p>Streamlining the multidisciplinary meeting to prioritise discussion of patients with breast cancer</p> <p>Aaditya Sinha^{1,2}, <u>Katie Badawy</u>^{1,2}, Belul Shifa^{1,2}, Zhane Peterson^{1,2}, Mohamed Attia^{1,2}, Arnie Purushotham^{1,2}</p> <p>¹King's College London, London, UK, ²Guy's and St Thomas' NHS Foundation Trust, London, UK</p>

6	Metastatic breast cancer	CDK4/6 inhibitors compared to weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis: a retrospective study <u>Roya Behrouzi</u> ¹ , Anne Armstrong ¹ , Sacha Howell ^{1,2} ¹ The Christie NHS Foundation Trust, Manchester, UK, ² Division of Cancer Sciences, The University of Manchester, Manchester, UK
7	Genetics/Screening/ Early detection	How comfortable are you in consulting pregnant and lactating women for breast imaging? <u>Sau Lee Chang</u> ¹ , Justice Reilly ¹ Royal Marsden Hospital
8	Other	Contrast-Enhanced Mammography (CEM) versus Dynamic Contrast-Enhanced MR Breast (DCE-MR Breast) in local staging of breast cancer: A comparison of the sensitivity and background parenchymal enhancement <u>Sau Lee Chang</u> ¹ , Steven Allen ¹ , Basrull Bhaludin ¹ , Kate Downey ¹ , Victoria Sinnott ¹ , Julie Scudder ¹ , Tanja Gagliardi ¹ ¹ Royal Marsden Hospital, London, UK
9	Living with BC/QoL/ Patient perspective/ Supportive care	Sleep disturbance amongst the breast cancer population - a single-centre prospective experience <u>Amani Chowdhury</u> ¹ , E Scott ¹ , Amy Guppy ¹ , Andreas Makris ¹ ¹ Mount Vernon Cancer Centre, UK
10	Trials in progress	SENTINUS: Technical feasibility and diagnostic accuracy of contrast enhanced ultrasound to identify sentinel lymph node metastases in breast cancer patients following training of imaging specialists <u>Karina Cox</u> ¹ , Priya Palanisamy ¹ , Jenny Weeks ¹ , Jaideep Rait ¹ , Nisha Sharma ² , Catherine Harper-Wynne ¹ , Rebecca Millican-Slater ² , Tamara Suaris ³ , Jennifer Hu ³ , Ali Sever ⁴ , Anum Pervez ⁴ , Sreenivas Muthyala ⁵ , Cliona Kirwan ⁶ , David Dodwell ⁷ , Matthew Wallis ⁸ , Andrea Marshall ⁹ , Sophie Gasson ⁹ , Janet Dunn ⁹ ¹ Maidstone And Tunbridge Wells NHS Trust, Maidstone, UK, ² Leeds Teaching Hospital NHS Trust, Leeds, UK, ³ Barts Health NHS Trust, London, UK, ⁴ Guy's and St Thomas' NHS Foundation Trust, London, UK, ⁵ University Hospitals Coventry & Warwickshire NHS Trust, Coventry, UK, ⁶ University of Manchester, Manchester, UK, ⁷ Oxford University Hospitals NHS Trust, Oxford, UK, ⁸ Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, ⁹ The University of Warwick, Coventry, UK
11	Other	Accuracy of MRI in Breast Cancer Imaging- A Study into Radiological and Pathological Concordance <u>Aisling Daly</u> ¹ , Norlinda Johnston ¹ ¹ Nimda
12	Treatment/Novel agents	Single centre experience of the adoption of self-administered HER2-directed therapy in patients with breast cancer <u>Vikash Dodhia</u> ¹ , <u>Wendy Ng</u> ¹ , Amy Guppy ¹ , Stephanie Sutherland ¹ , Margolzata Wojtas ¹ , Karen Harrold ¹ , Aolat Adisa ¹ , Tome Tapiwa ¹ , David Miles ¹ , Andreas Makris ¹ ¹ Mount Vernon Cancer Centre



13	Other	<p>Digital image analysis and a novel set of cell line samples as aids in the development of a quantitative external quality assessment programme for Ki-67</p> <p>Andrew Dodson¹, Fitim Berisha¹, Dawn Wilkinson¹, Suzanne Parry¹, Lila Zabaglo¹ ¹UK NEQAS, London, UK</p>
14	Living with BC/QoL/ Patient perspective/ Supportive care	<p>Patient and Public Involvement (PPI) – It's role in keeping the ATNEC trial open to recruitment.</p> <p>Helen-Teresa Edwards², Janice Rose², Sophie Gasson¹, Sophie Nicholls¹, Natalie Hammonds¹, Janet Dunn¹, Amit Goyal³ ¹Warwick Clinical Trials Unit, University of Warwick, ²Independent Cancer Patients' Voice, London, ³Royal Derby Hospital, Derby</p>
15	Prevention/Lifestyle	<p>A pilot study of the impact of a personalised online yoga and wellness programme on quality of life in women treated for breast cancer</p> <p>Donna Egbeare¹, Jacqueline Rees-Lee¹, India Gooderham² ¹Torbay And South Devon NHS Foundation Trust, Torquay, UK, ²Gentle Recovery Programme, Ashburton, UK</p>
16	Other	<p>A Novel Way to Increase Recruitment to a National Multicentre Study. The ChamPionSE Scheme for the ABS ASPIRE Breast Pain Pathway Rapid Evaluation Project</p> <p>Kathryn Ellis¹, Jo Fields², Suzanne Halliday³, Rajiv Dave¹, Thomas Hubbard⁴, Jennifer Hu⁵, Anna Isaac⁶, Alice Cui⁷, Ramsay Cutress⁸, Shelley Potter, Karina Cox⁹, Leena Chagla¹⁰, Chris Holcombe¹¹ ¹Manchester University NHS Foundation Trust, ²Hampshire Hospitals NHS Foundation Trust, ³Surrey and Sussex Healthcare NHS Trust, ⁴Faculty of Health and Life Sciences, University of Exeter, ⁵Barts Health NHS Trust, ⁶Belfast City Hospital, ⁷Wythenshaw Hospital, ⁸University of Southampton, ⁹Maidstone and Tunbridge Wells NHS Trust, ¹⁰St Helens and Knowsley Hospitals NHS Trust, ¹¹Liverpool University Hospital</p>
17	Other	<p>Does primary care breast examination of patients, presenting with a solitary symptom of breast pain, alter the pathway for the patient?</p> <p>Katy S Ellis¹ ¹Manchester University Foundation Trust, Manchester, Greater Manchester</p>
18	Treatment/Novel agents	<p>Risk of incomplete ovarian function suppression (OFS) using gonadotropin-releasing hormone (GnRH) agonists and antagonists in premenopausal women with estrogen receptor (ER)-positive breast cancer</p> <p>Ansaam El-Sherif^{1,2}, Elizabeth Lewis-Orr³, Mae Eales³, Nia Roberts⁴, Christiana Kartsonaki⁵ ¹Sheffield Teaching Hospitals NHS Foundation Trust, ²School of Medicine and Population Health, University of Sheffield, ³Medical Sciences Division, University of Oxford, ⁴Bodleian Libraries, University of Oxford, ⁵Nuffield Department of Population Health, University of Oxford</p>

19	Genetics/Screening/ Early detection	Mini Review: Breast Cancer Care in Individuals with Differences of Sexual Development <u>Buket Ertansel</u> ¹ , Shohba Rajagopal, Siya Lodhia, George Boutsikos, Dibyesh Banerjee ¹ St George's Hospital, London
20	Surgery	Exploring outcomes and experiences of women denied immediate breast REconstruction after maSTectOmy for bREast cancer during the COVID-19 pandemic - The RESTORE C19 Study <u>Katherine Fairhurst</u> ¹ , Rajiv Dave, Rachel L O'Connell, Raghavan Vidya, P.G. Roy, Stuart A McIntosh, Patricia Fairbrother, Jo Skillman, Leila Rooshenas, Shelley Potter ¹ University Of Bristol, Bristol, UK
21	Metastatic breast cancer	Inhibition of zinc transporters significantly reduces breast cancer cell motility, in vitro <u>Georgia Farr</u> ¹ , Samuel Jones, Kathryn Taylor ¹ Cardiff University, Cardiff, UK
22	Metastatic breast cancer	Single cell analysis of paired lymph nodes and primary tumors in breast cancer patients <u>Marit Otterlei Fjørtoft</u> ^{1,2} , Karin Teien Lande ¹ , Inger Riise Bergheim ¹ , Margit Riis ³ , Øystein Garred ⁴ , Ole Christian Lingjærde ⁵ , June Myklebust ^{1,2,6} , Hege Russnes ^{1,2,4} , Kanutte Huse ^{1,6} , Inga Hansine Rye ^{1,2} ¹ Institute for Cancer Research, Oslo University Hospital, Oslo, Norway, ² Institute of Clinical Medicine, University of Oslo, Oslo, Norway, ³ Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway, ⁴ Division of Laboratory Medicine, Oslo University Hospital, Oslo, Norway, ⁵ Institute of Informatics, University of Oslo, Oslo, Norway, ⁶ KG Jebsen Centre for B cell Malignancies and Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway
23	Genetics/Screening/ Early detection	Implementation of Breast Cancer Choices: how a web-based patient decision aid for decisions about BRCA testing is implemented in real-world, mainstream cancer care settings <u>Rebecca Foster</u> ¹ , Gillian Crawford ² , Lesley Turner ³ , Kelly Kohut ^{1,4} , Kate Morton ¹ , Lucy Side ² , Jackie Chandler ⁵ , Kate Lippiett ^{1,6} , Diana Eccles ⁷ , Claire Foster ¹ ¹ Centre for Psychosocial Research in Cancer: CentRIC, School of Health Sciences, University Of Southampton, Southampton, UK, ² University Hospital Southampton NHS Foundation Trust, Southampton, UK, ³ Patient and public collaborator, Southampton, UK, ⁴ St George's University Hospitals NHS Foundation Trust, London, UK, ⁵ Wessex Academic Health Science Network, Southampton, UK, ⁶ Wessex Cancer Alliance, Southampton, UK, ⁷ Faculty of Medicine, University of Southampton, Southampton, UK
24	Living with BC/QoL/ Patient perspective/ Supportive care	ATNEC – Patient Experience Sub-Study (IRSCTN: 36585784): What Patients Think About Taking Part in Breast Cancer Treatment De-Escalation Trials Janet Dunn ¹ , <u>Sophie Gasson</u> ¹ , Sophie Nicholls ¹ , Jan Rose ² , Helen Teresa Edwards ² , Andrea Marshall ¹ , Natalie Hammonds ¹ , Beatrix Elsberger ³ , Amit Goyal ⁴ ¹ Warwick Clinical Trials Unit, Coventry, UK, ² Independent Cancer Patients' Voice, London, UK, ³ NHS Grampian, Aberdeen, Scotland, ⁴ University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK



25	Trials in progress	FAST MRI - Diagnostic Yield study for Average Mammographic screening Density (DYAMOND): Protocol of a trial in progress Lyn Jones ¹ , Rebecca Geach ¹ , Janet Dunn ² , Andrea Marshall ² , Sian Taylor-Phillips ² , Sam Harding ¹ , Abeer Shaaban ⁵ , Mark Halling-Brown ³ , Sarah Vinnicombe ⁴ , Janice Rose ¹ , Helen Matthews ¹ , Abi Loose ¹ ¹ North Bristol NHS Trust, Bristol, UK, ² Warwick Clinical Trials Unit, Warwick, UK, ³ Royal Surrey NHS Foundation Trust, Guilford, UK, ⁴ Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, UK, ⁵ University of Birmingham, Birmingham, UK
26	Surgery	Can preoperative upfront magnetic (Magseed®) localisation of impalpable screen detected breast lesions improve workflow and simplify patient pathways? Zoe Goldthorpe ¹ , Vrinda Sukumaran ¹ ¹ Somerset FT, Taunton, UK
27	Early breast cancer	Practice patterns in ongoing neoadjuvant ATNEC trial for patients with cT1-3N1M0 breast cancer: node marking, response to neoadjuvant chemotherapy (NACT) and breast conservation rates Amit Goyal ¹ , Andrea Marshall ² , Sophie Nicholls ² , Natalie Hammonds ² , Beatrix Elsberger ³ , Duncan Wheatley ⁴ , Abeer Shaaban ⁵ , Shama Puri ¹ , Janice Rose ⁶ , Helen-Teresa Edwards ⁶ , Zohal Nabi ⁷ , Samreen Ahmed ⁸ , Helen Higgins ² , Janet Dunn ² ¹ Royal Derby Hospital, Derby, ² Warwick Clinical Trials Unit, Coventry, ³ Aberdeen Royal Infirmary, Aberdeen, ⁴ Royal Cornwall Hospital, Treliske, ⁵ Queen Elizabeth Hospital, Birmingham, ⁶ Independent Cancer Patient's Voice, London, ⁷ National Radiotherapy Trials Quality Assurance Group, London, ⁸ Leicester Royal Infirmary, Leicester
28	Metastatic breast cancer	Prevalence and referral sources of metastatic breast cancer at the Kent Oncology Centre Maidstone & Tunbridge Wells; 2019 - 2023 Catherine Harper-Wynne ¹ , Emily Parsons ¹ , Russell Burcombe ¹ , Tabitha Curtis, Louise Griva ¹ , Annabel Kennedy ¹ , Kelly Morphew ¹ , Charlotte Moss ¹ , Claire Ryan ¹ Kent Oncology Centre -Maidstone & Tunbridge Wells NHS Trust, Maidstone, UK
29	Prevention/Lifestyle	Bespoke muscle resistance exercise (MRE) programme for use in a future clinical trial, following patient engagement program (PEP) in patients with advanced breast cancer (ABC) Catherine Harper-Wynne ¹ , Amanda Clarke ¹ , Glen Davison ² , Jennifer Glendenning ¹ ¹ Kent Oncology Centre -Maidstone Tunbridge Wells NHS Trust, Maidstone, UK, ² University of Kent, Canterbury, UK
30	Preclinical research	Elucidating the Functional Mechanisms of a Novel PTEN Long Non-Coding RNA in Breast Cancer Hana Hasna ¹ , Mariam El-Esnawy ¹ , Rim Elghandour ¹ , Ihab Younis ¹ ¹ Carnegie Mellon University in Qatar

31	Treatment/Novel agents	Targeting zinc transporters provides a potent treatment for triple negative and tamoxifen-resistant breast cancer preclinical mouse models <u>Adam Higgins</u> ¹ , Gillian Seaton ¹ , Richard Clarkson ¹ , Kathryn Taylor ² ¹ European Cancer Stem Cell Research Institute, Cardiff University, Cardiff, Wales, UK, ² School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, UK
32	Surgery	Neoadjuvant radiotherapy prior to mastectomy and breast reconstruction – a systematic review of oncological and aesthetic outcomes <u>Ken Weixing Ho</u> ¹ , Joseph Ward ² , Chiugo Ike ² , Paul Thiruchelvam ¹ , Aadil Khan ² , Daniel Leff ¹ ¹ Imperial College Healthcare NHS Trust, London, UK, ² The Royal Marsden Hospital NHS Foundation Trust, London, UK
33	Early breast cancer	I'm sure it is good for me but I don't quite understand why – patients' experience of adjuvant bisphosphonates for early breast cancer Elisavet Theodoulou ¹ , Janet Brown ¹ , <u>Ingunn Holen</u> ¹ ¹ Division of Clinical Medicine University of Sheffield, Sheffield, UK
34	Surgery	Axillary management of a positive sentinel lymph node biopsy in the era of Abemaciclib in early Breast cancer <u>Thomas Hubbard</u> ^{1,2} , Hannah Knight ² ¹ University Of Exeter, Exeter, UK, ² Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK
35	Living with BC/QoL/ Patient perspective/ Supportive care	External Breast Forms and the custom fit fallacy; why our innovative custom fit system fails. <u>Samantha Jackman</u> ¹ ¹ Boost Innovations Ltd, Church Hill, Calstock, UK
36	Prevention/Lifestyle	The Impact of Body Mass Index on Pathological Complete Response Following Neoadjuvant Chemotherapy in Operable Breast Cancer <u>Richa Jaiswal</u> ¹ , Emma Blower ¹ , Helen Innes ¹ , Raj Sripadam ¹ , Petros Yiannoullou ¹ , Leena Chagla ¹ ¹ St Helens and Knowsley Hospitals and Trust, UK, Prescot, UK
37	Pathology	Osteopontin (OPN) as a Potential Biomarker for Early Detection of Ductal Carcinoma in Situ (DCIS) <u>Eaman Javed</u> ¹ ¹ University Of Liverpool, Liverpool, UK, ² Clatterbridge Cancer Centre, Liverpool, UK, ³ Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK
38	Genetics/Screening/ Early detection	Roll out and influence on practice of the Talking about Risk, Uncertainties of Testing in Genetics (TRUSTING) educational programme <u>Valerie Jenkins</u> ¹ , Ruth Habibi ¹ , <u>Dame Lesley Fallowfield</u> ¹ ¹ SHORE-C, BSMS, University of Sussex, Brighton, UK



39	Genetics/Screening/ Early detection	Interplay between tumor size and vitamin D receptor (VDR) polymorphisms in breast cancer prognosis: A prospective cohort study Hampus Lindgren ¹ , David Ademi ¹ , Christopher Godina ¹ , Helga Tryggvadottir ¹ , Karolin Isaksson ^{2,3} , Helena Jernström ¹ ¹ Clinical Sciences Lund, Oncology, Lund University, Lund, Sweden, ² Clinical Sciences Lund, Surgery, Lund University, Lund, Sweden, ³ Central Hospital Kristianstad, Kristianstad, Sweden
40	Treatment/Novel agents	Zinc transporters: a potent therapeutic target for treatment of triple-negative and tamoxifen-resistant breast cancers Samuel Jones ¹ , Miss Georgia Farr ¹ , Kathryn Taylor ¹ ¹ Welsh School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff
41	Genetics/Screening/ Early detection	Models for predicting the risk of breast cancer: a systematic review Federica Re ^{1,2} , Ansaam El-Sherif ^{6,7} , Miss Natnicha Manaboriboon ³ , Iwan G. A. Raza ² , Alexandra Shipley ² , Lucy E. Thompson ² , Catherine Tiplady ² , Rumbidzai Mucheke ⁴ , Roxanna E. Abhari ^{1,2,8} , Christiana Kartsonaki ^{1,9} ¹ Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK, ² Medical Sciences Division, University of Oxford, Oxford, UK, ³ Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand, ⁴ Oxford University Hospitals NHS Foundation Trust, Oxford, UK, ⁵ Medical Research Council Population Health Research Unit (MRC PHRU), Nuffield Department of Population Health, University of Oxford, Oxford, UK, ⁶ University of Sheffield, Sheffield, UK, ⁷ Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK, ⁸ Royal Infirmary of Edinburgh, Edinburgh, UK, ⁹ MRC Population Health Research Unit, Oxford, UK
42	Other	Breast Cancer MDT Standard of Care Audit St George's Hospital Muireann Kelleher ¹ , Georgios Boutsikos ¹ , Catherine Cafferkey ¹ , Nadine Betambeau ¹ , Muhammad Mangat ¹ , Abhinav Jha ¹ , Shahrooz Mohammadi ¹ , Fiona Kyle ¹ , Sarah Tang ¹ , Karis McFeely ¹ , Lisanne Khoo ¹ ¹ St George's Healthcare NHS Foundation Trust, London, UK
43	Genetics/Screening/ Early detection	Acceptability of de-intensified screening for women at low risk of breast cancer: a randomised online experimental study in England Charlotte Kelley Jones ¹ , Suzanne Scott ² , Jo Waller ² ¹ King's College London, UK, ² Queen Mary University London, UK

44	Prevention/Lifestyle	<p>Pre- and postoperative antioxidant use, aryl hydrocarbon receptor (AhR) activation and clinical outcome in different treatment groups of breast cancer patients</p> <p>Linn Nilsson^{1,2}, Somayeh Khazaei¹, Helga Tryggvadottir^{1,3}, Sofie Björner¹, Alessandra Bressan¹, Karin Jirström⁴, Gabriel Adrian^{1,3}, Anna-Karin Falck⁵, Signe Borgquist⁶, Karolin Isaksson^{7,8}, Helena Jernström¹</p> <p>¹Clinical Sciences Lund, Oncology, Lund University, Lund, Sweden, ²Medical Physics and Engineering, Växjö Central Hospital and Research and Development, Region Kronoberg, Växjö, Sweden, ³Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden, ⁴ Clinical Sciences Lund, Therapeutic Pathology, Lund University, Lund, Sweden, ⁵Surgery, Helsingborg Hospital, Helsingborg, Sweden, ⁶Oncology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ⁷Clinical Sciences Lund, Surgery, Lund University, Lund, Sweden, ⁸Surgery, Central Hospital Kristianstad, Kristianstad, Sweden</p>
45	Early breast cancer	<p>Impact of Prosigna test on treatment decision in lymph node negative early breast cancer - a prospective multicenter study (EMIT1)</p> <p>Hege Oma Ohnstad¹, Elin Borgen¹, Elin Mortensen², Marianne B Brekke³, Lars Andreas Akslen⁴, Emiel AM Janssen⁵, Gry A Geitvik¹, Maria C Rypdal¹, Anita Langerød¹, Eline H Halset¹, Egil S Blix², Sunil X Raj³, Hans P Eikesdal⁴, Bjørnar Gilje⁵, Helle Skjerven⁶, Ellen Schlichting¹, Kristin V Reinertsen¹, Ragnhild S Falk¹, Hege G Russnes¹, Bjørn Naume¹</p> <p>¹Oslo University Hospital, Oslo, Norway, ²University of North Norway, Tromsø, Norway, ³St.Olav Hospital, Trondheim, Norway, ⁴Haukeland University Hospital, Bergen, Norway, ⁵Stavanger University Hospital, Stavanger, Norway, ⁶Vestre Viken Hospital Trust, Drammen, Norway</p>
46	Early breast cancer	<p>A review into the role of validated tools, predict and nottingham prognostic index, for guiding decisions on tumour profiling test referrals within our trust</p> <p>Tylan Lucas¹, Miss Vedika Apte², Neha Chopra¹, Amna Sheri¹, Jackie Newby¹, Judy King¹</p> <p>¹Royal Free Hospital NHS Foundation Trust, London, UK, ²University College London Medical School, London, UK</p>
47	Trials in progress	<p>The HER2-RADiCAL study (Response ADaptive CAre pLan) – Tailoring treatment for HER2 positive early breast cancer</p> <p>Iain Macpherson¹, Stuart McIntosh², Lucy Kilburn³, Holly Tovey³, Laura Moretti³, Katie Goddard³, Indrani Bhattacharya³, Clinton Boyd², Cliona Kirwan⁴, Ciara O'Brien⁴, Duncan Wheatley⁵, Jennifer Glendenning⁶, Mairead Mackenzie⁷, Hilary Stobart⁷, Claire Snowdon³, Andrew Wardley⁸, Abeer Shaaban⁹, Peter Hall¹⁰, David Cameron¹⁰, Judith Bliss³</p> <p>¹University of Glasgow, Glasgow, UK, ²The Queen's University of Belfast, Belfast, UK, ³Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, UK, ⁴The Christie NHS Foundation Trust, Manchester, UK, ⁵Royal Cornwall Hospitals NHS Trust, Truro, UK, ⁶East Kent Hospitals NHS Foundation Trust, Canterbury, UK, ⁷Independent Cancer Patients' Voice, London, UK, ⁸Outreach Research & Innovation Group, Manchester, UK, ⁹University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, ¹⁰The University of Edinburgh, Edinburgh, UK</p>

48	Prevention/Lifestyle	The impact of a breast cancer diagnosis on lifestyle behaviours - a mixed methods study <u>Lauren Matheson</u> ¹ , Jo Brett ¹ , Lucy McGeagh ¹ , Julie Bennett ¹ , Emma Davies ¹ , Eila Watson ¹ ¹ Oxford Brookes University, Oxford, UK
49	Radiotherapy	Results of survey on De-intensification of breast or chest wall radiotherapy following pathological complete response to neoadjuvant chemotherapy in the early breast cancer patients <u>Shaveta Mehta</u> ¹ , Jane Dufton ¹ ¹ Clatterbridge Cancer Centre, Liverpool, UK
50	Early breast cancer	Assessment of response to neoadjuvant chemotherapy in patients with T1-T3 node negative breast cancer- single centre experience Aymen Alaude ¹ , Jane Dufton ¹ , Helen Wong ¹ , <u>Shaveta Mehta</u> ¹ ¹ Clatterbridge Cancer Centre, Liverpool, UK
51	Early breast cancer	Axillary Lymph node Micro-metastasis and Oncotype DX Recurrence Score: Impact on adjuvant treatment in early breast cancer <u>Anam Mumtaz</u> ¹ , Szimona Szoradova ² , Hazem Khout ¹ , Nadia Gilani ¹ ¹ Nottingham Breast Institute, Nottingham University Hospital, NHS Trust, Nottingham, UK, ² Department of Oncology, Nottingham University Hospital, NHS Trust, Nottingham, UK
52	Other	Interval Breast Cancer in a One-stop symptomatic Breast Unit <u>Asma Munir</u> ¹ , Emine Demiral ¹ , Anita Huws ¹ , Sohail Khan ¹ , Saira Khawaja ¹ , Yousuf Sharaiha ¹ ¹ Prince Philip Hospital, Llanelli, UK
53	Living with BC/QoL/ Patient perspective/ Supportive care	Mode of Recurrence/ Metastasis Detection in Breast cancer survivors <u>Asma Munir</u> ¹ , Anita Huws ¹ , Sohail Khan ¹ , Yousuf Sharaiha ¹ , Saira Khawaja ¹ ¹ Prince Philip Hospital, Llanelli, UK
54	Trials in progress	ATNEC: A multicentre, randomised trial investigating whether axillary treatment can be avoided in cT1-3N1M0 breast cancer patients with no residual axillary nodal disease post-neoadjuvant chemotherapy <u>Sophie Nicholls</u> ¹ , Natalie Hammonds ¹ , Andrea Marshall ¹ , Duncan Wheatley ² , Beatrix Elsberger ³ , Janice Rose ⁴ , Helen-Teresa Edwards ⁴ , Zohal Nabi ⁹ , Shama Puri ⁵ , Tara Homer ⁶ , Luke Vale ⁶ , Samreen Ahmed ⁷ , Abeer Shaaban ⁸ , Julie Bruce ¹ , Sophie Gasson ¹ , Helen Higgins ¹ , Janet Dunn ¹ , Amit Goyal ⁵ ¹ Warwick Clinical Trials Unit, University of Warwick, Coventry, ² Royal Cornwall Hospital, Treliske, ³ Aberdeen Royal Infirmary, Aberdeen, ⁴ Independent Cancer Patients' Voice, London, ⁵ Royal Derby Hospital, Derby, ⁶ Newcastle University, Newcastle-upon-Tyne, ⁷ Leicester Royal Infirmary, Leicester, ⁸ Queen Elizabeth Hospital,

55	Other	Evidence of significant differences in the quality of PD-L1 immunohistochemical testing in triple negative breast cancer: results from external quality assessment Andrew Dodson ¹ , <u>Suzanne Parry</u> ¹ ¹ UK NEQAS ICC & ISH, London, UK
56	Other	Ensuring inclusivity of patient participation in clinical trials Aaditya Sinha ^{1,2} , Lucy Barwel ¹ , Hannah Jeffery ^{1,2} , <u>Zhane Peterson</u> ^{1,2} , Belul Shifa ^{1,2} , Mohamed Attia ^{1,2} , Katie Barawy ¹ , Prof. Arnie Purushotham ^{1,2} ¹ King's College London, London, UK, ² Guy's and St Thomas' NHS Foundation Trust, London, UK
57	Preclinical research	Talinflumate as a potential supplement in breast cancer treatment? <u>Ritika Rampal</u> ^{1,2} , Arindham Pramanik ³ , Louis Mcloughlin ¹ , Radhika Aiyappa-Maudsley ¹ , Baek Kim ^{1,2} , Thomas Hughes ^{1,4} ¹ School of Medicine, University of Leeds, Leeds, UK, ² Department of Breast and Reconstructive Surgery, St James' University Hospital, Leeds, UK, ³ Amity Institute of Biotechnology University, Amity University, Noida- Delhi, India, ⁴ School of Science, Technology and Health, York St John University, York, UK
58	Preclinical research	Inhibiting PTP1B in tumour conditioned macrophages promotes breast cancer growth by modulating tumour-promoting genes <u>Neve Elisa Read</u> ¹ , Martina Mesiarikova ¹ , Susan H Berry ¹ , Mirela Delibegovic, Graeme Murray, Valerie Speirs, Heather M Wilson ¹ University of Aberdeen, Aberdeen, UK
59	Early breast cancer	Going beyond: enabling transcriptomics-based precision breast oncology <u>Carlos Ronchi</u> ¹ , Syed Haider ² , Cathrin Briskin ^{1,2} ¹ EPFL, Lausanne, Switzerland, ² ICR, London, UK
60	Living with BC/QoL/ Patient perspective/ Supportive care	"Working together for the better": Patient and Public Involvement (PPI) in the ATNEC Trial – What is our role? <u>Janice Rose</u> ¹ , Helen-Teresa Edwards ¹ , Sophie Gasson ² , Sophie Nicholls ² , Natalie Hammonds ² , Janet Dunn ² , Amit Goyal ³ ¹ Independent Cancer Patient's Voice, London, ² Warwick Clinical Trials Unit, University of Warwick, Coventry, ³ Royal Derby Hospital, Derby
61	Early breast cancer	Gut microbiota predict efficacy of neoadjuvant systemic therapy in patients with early breast cancer <u>Kirsty Ross</u> ^{1,2,4} , Ben Nichols ² , Rodanthi Papadopoulou ² , Martin Macleod ¹ , Judith Fraser ¹ , Sophie Barrett ¹ , Katy Teo ³ , Elizabeth Mallon ³ , Aula Ammar ⁴ , Joanne Edwards ⁴ , Jeff Evans ^{1,4} , Konstantinos Gerasimidis ² , Iain R Macpherson ^{1,4} ¹ Beatson West of Scotland Cancer Centre, Glasgow, Scotland, UK, ² School of Medicine, University of Glasgow, Glasgow, Scotland, UK, ³ Pathology Department, Queen Elizabeth University Hospital, NHS Greater Glasgow & Clyde, Glasgow, Scotland, UK, ⁴ School of Cancer Sciences, University of Glasgow, Glasgow, Scotland, UK

62	Other	Rapid Access Breast Oncology Clinic in University Hospital Southampton NHS Foundation Trust: A quality improvement project <u>Constantinos Savva</u> ¹ , Sarah Ormerod ² , Angela Barling ² , Ramsey Cutress ^{1,2} , Ellen Copson ^{1,2} ¹ University Of Southampton, Southampton, UK, ² University Hospital Southampton NHS Foundation Trust, Southampton, UK
63	Treatment/Novel agents	Identifying genetic alterations that sensitise breast cancer cell lines to mTOR inhibitor and ATR inhibitor <u>Jogitha Selvarajah</u> ¹ , Marc Lorentzen, Charlotte Bevan ¹ Imperial College London, London
64	Genetics/Screening/ Early detection	Incidental lobular neoplasia on core biopsy performed for microcalcification and the recommended mammographic surveillance – a small study <u>Laura Shepherd</u> ¹ , Aarthi Parthasarathy ¹ , Ankita Singhanian ¹ , Soujanya Gadde ¹ , Susan Pritchard ¹ ¹ Manchester Foundation Trust, Manchester, UK
65	Living with BC/QoL/ Patient perspective/ Supportive care	The Patient Roles and Responsibilities Scale (PRRS): a psychometrically robust and useful tool to measure what matters most to patients <u>Valerie Shilling</u> ¹ , Rachel Starkings, Valerie Jenkins, Dame Lesley Fallowfield ¹ Brighton And Sussex Medical School, Brighton, UK
66	Preclinical research	Glucocorticoids and Tissue Transglutaminase 2: implications in Triple Negative Breast Cancer <u>Shubhankar Sinha</u> ¹ , Melanie Flint ¹ , Nicolas Stewart ¹ , Hazel Hunt ² ¹ University of Brighton, Brighton, UK, ² Corcept Therapeutics, San Francisco, USA
67	Other	Fibroblast growth factor receptor 1 (FGFR1) and its role in luminal breast cancer <u>Therese Sørli</u> ^{1,2} , MSc Torbjørn Lien ¹ , Sushil Dhakal ¹ , Helga Bergholtz ¹ , Jens Henrik Norum ¹ ¹ Oslo University Hospital, Oslo, Norway, ² University of Oslo, Oslo, Norway
68	Preclinical research	The Obesity Paradox Associated with Breast Cancer Risk Pre- and Post-menopausal Women Abigail Dodson ¹ , Katie Hanna ¹ , Kerri Palmer ¹ , Ehab Husain ² , Beatrix Elsberger ² , Yazan Masannat ² , Gerard Lip ² , Nicola Spence ³ , Justin Rochford, <u>Valerie Speirs</u> ¹ ¹ University of Aberdeen, Aberdeen, UK, ² Aberdeen Royal Infirmary, Aberdeen, UK, ³ Raigmore Hospital, Inverness, UK



69	Trials in progress	<p>OPTIMA, a randomised trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in high risk early breast cancer.</p> <p>Rob Stein¹, Andreas Makris², Iain MacPherson³, Luke Hughes-Davis, Andrea Marshall⁴, Georgina Dotchin⁴, David A. Cameron⁵, Belinda E. Kieley⁶, Bjørn Naume⁷, Caroline Wilson⁸, Anne Armstrong⁹, Helena M. Earl¹⁰, Daniel W. Rea¹¹, Carmel Conefrey¹², Nigel Stallard⁴, Victoria Harmer¹³, Abeer Shaaban¹⁴, Karen Taylor⁵, Peter S Hall⁵, Stuart McIntosh¹⁵, Bethany Shinkins⁴, Leila Rooshenas¹², Chris McCabe¹⁵, Sarah E. Pinder¹⁶, Jenny Donovan¹², John Bartlett⁵, Adrienne Morgan¹⁷, Janet Dunn⁴</p> <p>¹UCL (University College London)/ UCLH, London, UK, ²Mount Vernon Cancer Centre, Northwood, UK, ³University of Glasgow, Glasgow, UK, ⁴University of Warwick, Coventry, UK, ⁵The University of Edinburgh, Edinburgh, UK, ⁶The University of Sydney, Sydney, Australia, ⁷Oslo University Hospital, Oslo, Norway, ⁸Weston Park Cancer Centre, Sheffield, UK, ⁹The Christie Hospital, Manchester, UK, ¹⁰University of Cambridge, Cambridge, UK, ¹¹University of Birmingham, Birmingham, UK, ¹²University of Bristol, Bristol, UK, ¹³Imperial College Healthcare NHS Trust, London, UK, ¹⁴University Hospitals Birmingham, Birmingham, UK, ¹⁵Queen's University Belfast, Belfast, UK, ¹⁶King's College London, London, UK, ¹⁷Independent Cancer Patients' Voice, London, UK</p>
70	Living with BC/QoL/ Patient perspective/ Supportive care	<p>A UK study exploring the attitudes and experiences of patients living with metastatic breast cancer with regard to clinical research: A patient advocate-academic collaborative study</p> <p>Lesley Stephen¹, Janet Dunn², Claire Balmer², Sophie Gasson², Nada Elbeltagi², Ellen Copson³, Carlo Palmieri⁴</p> <p>¹Make 2nds Count, Edinburgh, Scotland, ²University of Warwick, Coventry, UK, ³University of Southampton, Southampton, UK, ⁴University of Liverpool, Liverpool, UK</p>
71	Preclinical research	<p>Deregulation of Minor Introns Splicing in Breast Cancer Cells</p> <p>Fiza Tarlochan¹, Zoya Farooqui¹, Ihab Younis¹</p> <p>¹Carnegie Mellon University in Qatar</p>
72	Metastatic breast cancer	<p>"There's always hope": improving access to clinical trials for people living with secondary breast cancer</p> <p>Sarah Thomas¹</p> <p>¹Make 2nds Count, Edinburgh, UK</p>
73	Early breast cancer	<p>Proliferative, immune and molecular characteristics of oestrogen-receptor positive, human epidermal growth factor receptor negative early breast cancer in patients aged 70 years and older.</p> <p>Jasmin V. Waterhouse^{1,2}, Elena López-Knowles^{2,3}, Anastasia Alataki^{2,3}, Lila Zabaglo⁴, Marta Lubowiecki^{2,3}, Margaret Hills³, Kathryn Dunne^{2,3}, Nicolò M.L. Battisti¹, Matilde Coriano¹, Anh T. L. Dinh¹, Kally Sidhu⁴, Ruth Sardinha³, Alistair Ring^{1,2,6}, Maggie C. U. Cheang^{5,6}, Eugene Schuster^{2,6}</p> <p>¹Breast Unit, The Royal Marsden NHS Foundation Trust, London, UK, ²Royal Marsden Hospital, London, UK; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK, ³The Ralph Lauren Centre for Breast Cancer Research, The Royal Marsden NHS Foundation Trust, London, UK, ⁴UK National External Quality Assessment Scheme for Immunocytochemistry and In-Situ Hybridisation, London, UK, ⁵Clinical Trials and Statistics Unit (ICR-CTSU)- Division of Clinical Studies, The Institute of Cancer Research, London, UK, ⁶Joined senior authors</p>



74	Trials in progress	<p>The challenges of recruiting women with low risk ductal carcinoma in situ to a randomised controlled trial: the LORIS study experience</p> <p><u>Sally Wheelwright</u>¹, Lucy Matthews¹, Valerie Jenkins¹, Shirley May¹, Daniel Rea², Pat Fairbrother³, Claire Gaunt², Jennie Young², Sarah Pirrie², Matthew Wallis⁴, Lesley Fallowfield¹</p> <p>¹University Of Sussex, Brighton, UK, ²University of Birmingham, Birmingham, UK, ³Independent Cancer Patients' Voices, London, UK, ⁴Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK</p>
75	Living with BC/QoL/ Patient perspective/ Supportive care	<p>Attitudes to lifestyle interventions in early breast cancer patients: A survey of UK healthcare professionals</p> <p><u>Abigail Whittaker</u>¹, Catherine Harper-Wynne², Caroline Wilson³, Constantinos Savva¹, Rebecca Beeken⁴, Bernard Corfe⁵, Omolade Femi-Ajao⁶, Kajal Gokal⁷, Michelle Harvie⁸, Lucy McGeagh⁸, Rachel Rolph⁹, John Saxton¹⁰, Caroline Tweedie¹¹, Guillermo Villacampa¹², <u>Ellen Copson</u>¹</p> <p>¹University of Southampton, Southampton, UK, ²Kent Oncology Centre- Maidstone Tunbridge Wells NHS Trust, Maidstone, UK, ³Weston Park Cancer Centre, Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, UK, ⁴University of Leeds, Leeds, UK, ⁵Newcastle University, Newcastle, UK, ⁶University of Manchester, Manchester, UK, ⁷Loughborough University, Loughborough, UK, ⁸Oxford Brookes University, Oxford, UK, ⁹Oxford University, Oxford, UK, ¹⁰University of Hull, Hull, UK, ¹¹Gateshead Health NHS Foundation Trust, Gateshead, UK, ¹²Institute of Cancer Research, London, UK</p>
76	Prevention/Lifestyle	<p>Feasibility and efficacy of a randomised pilot study of the North of England Women's Diet and Activity - After early Breast Cancer intervention</p> <p><u>Caroline Wilson</u>¹, Katie Pickering², Sarah Wane³, Judith Cohen⁴, H Chao⁴, Helen Crank⁵, Annie Anderson⁶, Henry Cain⁷, Rob Copeland², J Gray⁸, J Hargreaves⁹, Richard McNally¹⁰, John Saxton¹¹</p> <p>¹Weston Park Cancer Centre, Sheffield, UK, ²Advanced Wellbeing Research Centre, Sheffield, UK, ³Department of Sport, Exercise and Rehabilitation, Northumbria University, UK, ⁴Hull Health Trials Unit, Hull, UK, ⁵Academy of Sport and Physical Activity, `Sheffield Hallam University, UK, ⁶Division of Population ~Health and Genomics, University of Dundee, UK, ⁷Department of breast surgery, Newcastle upon Tyne Hospitals NHS Trust, UK, ⁸Department of Nursing Midwifery and health, Northumbria University, UK, ⁹Carnegie School of Sport, Leeds Beckett ~University, UK, ¹⁰Population Health Sciences Institute, `newcastle University, uk, ¹¹department of sport, health and exercise science, University of Hull, UK</p>
77	Other	<p>Audit of Incidental Breast Lesions on Non-Dedicated Imaging: A Six-Month Analysis</p> <p><u>Joanna Wolska</u>¹, Sylvie Flais¹</p> <p>¹Imperial College Healthcare NHS Trust, London, UK</p>
78	Other	<p>Incidental Breast Lesions on Non-Breast-Dedicated Imaging: Identifying Highly Suggestive Malignancies – A Pictorial Review</p> <p><u>Joanna Wolska</u>¹, Sylvie Flais¹</p> <p>¹Imperial College Healthcare NHS Trust, London, UK</p>

79	Metastatic breast cancer	<p>The bone anabolic agent losartan reduces progression of lytic lesions in an in vivo model of breast cancer-induced bone disease</p> <p><u>Jacky Wong</u>¹, Lubaid Saleh¹, Holly Evans¹, Enrico Dall'Ara², Michelle Lawson¹, Ingunn Holen¹ ¹University Of Sheffield, Sheffield, UK, ²INSIGNEO Institute for in silico Medicine, Sheffield, UK</p>
80	Living with BC/QoL/ Patient perspective/ Supportive care	<p>Breast Cancer Now's Service Pledge: Using the power of the patient voice to improve breast cancer services</p> <p>Fran Berry¹, <u>Catherine Wood</u>¹, Zoe Harris¹, Kim Giffen¹ ¹Breast Cancer Now</p>
81	Metastatic breast cancer	<p>Measuring plasma, soluble Semaphorin-4D (SEMA4D): a potential non-invasive biomarker predictive of clinical outcomes within breast cancer patients with bone metastasis</p> <p><u>Steven Wood</u>¹, Walter Gregory², Fatma Gossiel¹, Richard Eastell¹, Mark Dunning¹, Gabriela Berg³, Janet Brown¹ ¹University Of Sheffield, Sheffield, UK, ²University of Leeds, Leeds, UK, ³Biomedica, Vienna, Austria</p>

